Ascensia Diabetes Care has launched a patient assistance programme in the US to provide broader access to its Eversense CGM system. Under the programme eligible patients starting or continuing with the Eversense CGM System will need to pay the first $100 of their out-of-pocket costs. Ascensia will then cover up to $300 of the remaining balance for each 90-day sensor. Any additional costs will be the system user’s responsibility. There is no news yet as to this programme becoming available in the UK.
Mary Puncochar, Head of Ascensia’s Region US, commented: “We hear from people living with diabetes and their healthcare providers how transformative the Eversense system can be in facilitating their diabetes management. People using the system appreciate how Eversense provides discretion with a removable transmitter, peace of mind through the on-body alerts, and the freedom that a 90-day sensor provides.”
The Eversense CGM System consists of an implanted fluorescence-based sensor, a smart transmitter worn over the sensor, and a mobile app for displaying glucose values, trends and alerts. The transmitter can also be removed, recharged and re-attached to the skin without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider.
For more on Eversense, CLICK HERE.
